Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|9|14|1133-1138

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.9, Iss.14, 2003-05, pp. : 1133-1138

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130

By Gelmon Karen   Belanger Karl   Soulieres Denis   Britten Carolyn   Chia Stephen   Charpentier Danielle   Chi Kim   Powers Jean   Walsh Wendy   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 445-453

Springer Publishing Company

Access to resources Recommend Favorite

Targeting T-Cell Adhesion Molecules for Drug Design

By  

Current Pharmaceutical Design, Vol. 12, Iss. 22, 2006-08 ,pp. : 2797-2812

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of T Cell Tolerance and Suppression in Cancer Mediated by Tumor-Associated Antigens and Hormones

By  

Current Cancer Drug Targets, Vol. 7, Iss. 1, 2007-02 ,pp. : 3-14

Bentham Science Publishers

Access to resources Recommend Favorite

Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 11, Iss. 3, 2012-12 ,pp. : 221-229

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical trials of active cancer immunotherapy

By Nawrocki Sergiusz   Mackiewicz Andrzej  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 8, 2007-08 ,pp. : 1137-1141

Informa Healthcare

Access to resources Recommend Favorite